A cute upper gastrointestinal bleeding (UGIB) is encountered commonly in emergency departments (EDs), and can result in serious morbidity and mortality. Despite remarkable advancements in medical treatments and endoscopic interventions, the mortality rate from acute UGIB remains high, at up to 14%. [1] [2] [3] Several risk-stratification tools have been developed to predict the outcomes of patients with UGIB. Among these, the Glasgow-Blatchford score (GBS) and Rockall score have been used commonly in clinical practice. 4, 5 The GBS was shown to be superior to the Rockall score in previous studies. 6 Patients with a GBS of 2 or less are considered to have a low risk and are eligible for outpatient management. 7 Although the GBS cut-off value for high-risk patients still is ambiguous, patients with a GBS greater than 7 were shown to have increased risks of significant bleeding and mortality. 8 In many studies, high-risk patients showed an extremely high mortality rate of up to 25%. 1, 9 Considering the poor outcomes of high-risk patients, it is critical to predict the clinical course of these patients in the ED, and provide timely and appropriate treatment.
For patients with nonvariceal UGIB, endoscopy is a gold standard procedure for diagnosis and treatment. High-risk patients are recommended to undergo early endoscopy, generally defined as an endoscopy within 24 hours of presentation. 10, 11 However, because endoscopy earlier than 24 hours was shown previously to have better outcomes in high-risk patients, 9 ,12 early endoscopy within 12 hours has been recommended for these patients. Furthermore, a randomized controlled study showed that urgent endoscopy performed shortly after ED admission significantly reduced hospital stay and costs. 13 Thus far, there have been few studies on the impact of urgent endoscopy on outcomes in high-risk patients with acute nonvariceal UGIB.
In this study, we investigated the clinical features and outcomes of high-risk patients with acute nonvariceal UGIB, and aimed to determine if urgent endoscopy improves outcomes.
Methods

Patient Selection
From January 1, 2005, to December 31, 2014, we included consecutive high-risk patients aged 18 years and older who underwent endoscopy for coffee-ground emesis, hematemesis, or melena, at the ED of a tertiary care center. High-risk patients were defined as those with a GBS greater than 7 at the initial ED presentation. Patients who had a GBS of 7 or less at ED presentation did not undergo endoscopy within 48 hours, and patients who had variceal bleeding, were transferred from other hospitals, and did not have evidence of UGIB on endoscopy were excluded. Because studies have reported substantially higher mortality in tumor bleeding, 1,2 we also excluded tumor bleeding in this study. Endoscopy was classified according to the time interval between the procedure and initial ED presentation, as follows: urgent endoscopy, fewer than 6 hours; elective endoscopy, 6 to 48 hours. At our hospital, endoscopy was available 24 hours per day, 7 days per week in the ED depending on the on-call gastroenterologist's decision. For all patients with acute nonvariceal UGIB in the ED, a proton pump inhibitor (PPI) infusion was initiated as soon as possible before endoscopy. This study was approved by our hospital's institutional review board.
Data Collection and Definition
Data including age, sex, clinical features, initial vital signs, laboratory findings, anticoagulation, timing and diagnosis of endoscopy, transfused packed red blood cells (pRBCs), primary endoscopic intervention, embolization, surgery, and comorbidities such as malignancy and cirrhosis were retrieved from medical records. Bleeding activity was classified using the Forrest classification.
14 Forrest Ia (spurting bleeding) and Ib (oozing bleeding) represent active hemorrhage stigmata; Forrest IIa (nonbleeding visible vessel), IIb (adherent clot), and IIc (flat pigmented spots) are signs of recent hemorrhage; and Forrest III (clean-based ulcer) represents lesions without active bleeding. The primary outcomes were mortality and rebleeding within 28 days of the ED visit. The secondary outcomes were packed red blood cell transfusion volume, need for intervention, intensive care unit stay, vasopressor use, and length of hospital stay. Rebleeding was defined as a decrease in hemoglobin (Hb) level of 2 g/dL or more after achieving a stable Hb level; new onset of fresh hematemesis, fresh hematochezia, or melena; or active bleeding seen on repeat endoscopy after the patient had stopped bleeding initially. 15 For patients with rebleeding, secondary endoscopic intervention was the first option, and subsequent embolization or surgery was performed according to the endoscopist's decision.
Statistical Analysis
Continuous variables are expressed as means AE SD, and categoric data are presented as absolute numbers and percentage frequencies. Differences in continuous variables were assessed with the Student t test. Differences in categoric variables were analyzed with the chisquare test. Of the clinical baseline characteristics, only patients with a P value less than .10 according to univariate analysis were considered as candidates for the multivariate model, which finally was determined with a backward stepwise variable selection procedure. The results of univariate and multivariate logistic regression analyses were summarized by estimating the odds ratio (OR) and respective 95% confidence interval (CI). A 2-tailed P value less than .05 was considered statistically significant. All statistical analyses were performed with SPSS version 18.0 (IBM, Armonk, NY).
Results
Patient Characteristics
A total of 961 patients were included. . There was no significant difference in GBS between groups. However, shock was more frequent (25.0% vs 18.2%; P ¼ .014) and systolic blood pressure was lower (107.6 AE 23.5 vs 111.7 AE 24.0 mm Hg; P ¼ .008) in the urgent group than in the elective group. Similarly, the Rockall score was higher in the urgent group than in the elective group (5.7 AE 2.2 vs 5.2 AE 2.1; P ¼ .001). Hb levels tended to be lower in patients with urgent endoscopy than in patients with elective endoscopy (9.7 AE 2.5 vs 10.0 AE 2.6 mg/dL; P ¼ .056). Table 2 shows the endoscopic data. Among the endoscopic diagnoses, peptic ulcer, including gastric and duodenal ulcers, was observed in 680 (67.8%) patients, followed by a Mallory-Weiss tear in 89 (9.3%), a Dieulafoy lesion in 44 (4.6%), and vascular ectasia in 22 (2.3%). The miscellaneous category included esophagitis, gastritis, mucosal oozing, and unidentified focus. Patients with urgent and elective endoscopy showed significant differences in bleeding cause (P ¼ .006). According to the Forrest classification, Forrest Ia was observed in 8.3%, Forrest Ib in 24.4%, Forrest IIa in 22.1%, Forrest IIb in 13.6%, Forrest IIc in 12.7%, and Forrest III in 19.0%. Active hemorrhage was identified on endoscopy more often in patients with urgent endoscopy than in patients with elective endoscopy (38.9% vs 23.3%; P < .001). As expected, endoscopic treatment was applied more frequently in the urgent group than in the elective group (69.5% vs 53.3%; P < .001). Twenty-one patients (3.7%) in the urgent group and 6 patients (1.5%) in the elective group failed primary endoscopic treatment. Of the 27 patients with failed endoscopic treatment, 15 underwent embolization, 4 underwent repeated endoscopic treatment, and 2 underwent surgery. The remaining 6 patients were monitored carefully with correction of coagulopathy and transfusion because no bleeding focus was found on endoscopy or angiography. Among patients 
Endoscopic Features
Outcomes According to Endoscopy Timing
Among the 961 patients, 24 (2.5%) died within 28-day and 100 (10.4%) experienced rebleeding. Table 3 shows the clinical outcomes according to endoscopy timing. The 28-day mortality rate was lower in patients with urgent endoscopy than in patients with elective endoscopy (1.6% vs 3.8%; P ¼ .034). However, there was no difference in rebleeding between groups (11.4% vs 9.0%; P ¼ .239). Patients with urgent endoscopy had a higher need for intervention (69.5% vs 53.5%; P < .001) and embolization (2.8% vs 0.5%; P ¼ .013), and required a larger transfusion volume (2.6 AE 2.5 vs 2.3 AE 2.1 pRBCs; P ¼ .047) than patients with elective endoscopy. Surgery was performed in 6 patients with urgent endoscopy; however, there was no statistically significant difference in the surgery rate between groups (1.1% vs 0%; P ¼ .087). Furthermore, there was no difference in intensive care unit admission, vasopressor use, and length of hospital stay between groups.
Cause of Rebleeding and Secondary Intervention
Of 100 patients with rebleeding, 8 (8.0%) died within 28-day. The causes of rebleeding are shown in Table 4 . Gastric ulcer was the most common cause, observed in 46 patients, followed by duodenal ulcer (17 patients). Furthermore, 51 and 49 patients showed Forrest I and II ulcers with 4 deaths in each Forrest group, respectively. For patients with rebleeding, secondary endoscopic treatment, embolization, and surgery was performed in 75, 13, and 1 patient, respectively; in the remaining 11 patients, no further treatment was conducted. No treatment was given to patients with no bleeding focus detected or in patients who refused treatment. Mortality was observed in 4 patients with secondary endoscopic treatment and in 4 patients without further treatment. 
Predictors of 28-Day Mortality and Rebleeding
Discussion
In this study, 28-day mortality was observed in 2.5% and rebleeding was detected in 10.4% of patients. Notably, urgent endoscopy was associated strongly with a lower mortality rate for high-risk patients. Approximately 60% of high-risk patients underwent urgent endoscopy. The urgent endoscopy group was more unstable hemodynamically with a higher incidence of shock, although there was no difference in GBS between groups. Nevertheless, the rebleeding rate was not different between groups, and the mortality rate was lower in patients with urgent endoscopy than in patients with elective endoscopy (1.6% vs 3.8%).
The endoscopy timing in patients with acute nonvariceal UGIB is controversial. According to the International Consensus Recommendations on nonvariceal UGIB, early endoscopy within 24 hours is recommended for most patients with acute nonvariceal UGIB. 16 However, several studies have shown that endoscopy earlier than 24 hours may benefit high-risk patients. In a recent study by Lim et al, 9 it was shown that endoscopy within 13 hours of presentation was associated with a lower mortality rate in high-risk (GBS ! 12), but not low-risk, nonvariceal UGIB. A prospective randomized study suggested that endoscopy within 12 hours of arrival at the ED and endoscopic therapy benefit patients with bloody nasogastric aspirate. 12 Therefore, accumulating evidence suggests that earlier endoscopy within 12 hours may provide better outcomes for select patients with a higher risk of bleeding. However, studies were limited about the benefit of much earlier endoscopy within 6 hours in high-risk patients with acute nonvariceal UGIB. A retrospective cohort study reported that immediate endoscopy with an average delay of 2 hours after hospital admission did not improve the clinical outcome in 81 consecutive patients with bleeding peptic ulcers. 17 Similarly, a randomized controlled study showed that urgent endoscopy within 6 hours did not reduce hospitalization or resource utilization. 18 However, the populations of these 2 studies was too small (<100) to compare mortality between the urgent and nonurgent endoscopy groups, in which there was no mortality. 17, 18 In another retrospective study of 169 high-risk patients with acute nonvariceal UGIB, there was no difference in mortality (8% vs 6%) and rebleeding (9% vs 8%) between the 2 endoscopy groups (<6 vs 6-12 h). 19 However, in a retrospective study from Taiwan, the emergent endoscopy group (<8 h) showed a lower mortality rate than the urgent endoscopy group (8-24 h) (1% vs 6%, respectively) in high-risk patients with nonvariceal UGIB, although the difference was not statistically significant. 20 This study showed that urgent endoscopy is associated significantly with a lower mortality rate in high-risk patients with acute nonvariceal UGIB. However, the urgent endoscopy group had a larger transfusion volume and more frequent need for intervention and embolization. The difference may be owing to more common high-risk endoscopic lesions in the urgent endoscopy group. Despite the high-risk bleeding stigmata in the urgent endoscopy group, there was no difference in rebleeding. Surgery was performed for 6 patients in the urgent endoscopy group, but not for patients in the elective group. Urgent endoscopy could be considered effective in identifying high-risk bleeding lesions, and providing endoscopic or additional intervention in a timely manner. This study was large scale but based on a retrospective analysis. Therefore, further prospective studies are required to confirm the effectiveness of urgent endoscopy in high-risk patients with nonvariceal UGIB.
Another important aspect is the selection of patients who will benefit from urgent endoscopy. Because many hospitals do not have the capability to provide endoscopy 24 hours a day and 7 days a week, it will be important to restrict urgent endoscopy for select patients only. Many studies defined high-risk patients as those with a GBS greater than 12, or by using other clinical parameters. 9, 20 In this study, we used a GBS greater than 7 to define high-risk patients. This definition was based on a previous prospective study in which the risk of significant bleeding requiring endoscopic and surgical intervention, as well as the risk of death, increased in patients with a GBS greater than 7. 8 On the basis of our findings, we suggest that high-risk patients with nonvariceal UGIB with a GBS greater than 7 should be considered candidates for urgent endoscopy.
Consistent with a previous study, 21 we found that failed primary endoscopic treatment and rebleeding were associated with substantially increased mortality (by 15-fold and 2.8-fold, respectively). In our study, the mortality rate was 18.5% for patients with failed primary endoscopic treatment and 8% for rebleeding patients. At our hospital, immediate embolization is usually the first option for patients with failed endoscopic treatment. Therefore, embolization was the mainstay intervention for patients with failed primary endoscopic treatment, whereas endoscopic retreatment was the major intervention for patients with rebleeding.
Another important finding of this study was that malignancy and cirrhosis were associated independently with increased mortality. Because we considered all-cause deaths as well as bleeding-related deaths, comorbidities could be important factors for in-hospital mortality in patients with acute nonvariceal UGIB. In this study, patients with malignancy and cirrhosis had an increased mortality risk of approximately 4-and 5-fold, respectively. For the Rockall clinical risk score, 2 or 3 points are given for liver failure and malignancy. 5 Past studies have shown that comorbidity is associated with significantly increased mortality in patients with nonvariceal UGIB. 22 Rebleeding was associated with high-risk endoscopic lesions, Forrest I and II ulcers, and coagulopathy in this study. As found in this study, active bleeding was more common in the urgent endoscopy group than in the elective endoscopy group, similar to many other studies. 17, 18 Active bleeding was shown to have high rebleeding and mortality rates, 55% and 11%, respectively, without endoscopic therapy. 23 A randomized controlled study showed that high-dose omeprazole before endoscopy accelerated the resolution of signs of bleeding in ulcers. 24 Although PPI administration before endoscopy was the standard therapy for patients with acute UGIB at our hospital, the length of PPI treatment might be too short to heal the bleeding lesion before endoscopy. The endoscopic treatment modality was not associated with rebleeding in this study. In past studies, mechanical or thermal therapy was shown to be superior to injection for reducing recurrent bleeding. 25, 26 Moreover, combined therapy reduced rebleeding more than monotherapy. In this study, combined therapy was used most frequently; however, there was no significant difference in rebleeding based on the endoscopic treatment modality. Furthermore, urgent endoscopy also was not associated with rebleeding. Our finding was consistent with those of previous studies showing no difference in rebleeding according to endoscopy timing. [17] [18] [19] However, the effect of early endoscopy on rebleeding still is controversial. A large retrospective study found that early endoscopic therapy was associated with a decreased risk of recurrent bleeding in high-risk patients with acute UGIB. 15 Therefore, this issue should be investigated further. Among patients with rebleeding, mortality was observed only in groups with endoscopic re-treatment or no further treatment, whereas patients with embolization or surgery had no deaths. The group with no further treatment showed an extremely high mortality rate of 36.4%. It seemed that there might be a difference in mortality according to secondary intervention modality in patients with rebleeding. Therefore, more intensive studies on the treatment strategy for patients with rebleeding are needed for better outcomes.
This study had some limitations. First, it was a retrospective observational study. Because data were retrieved from existing records, there could be missing information. However, because the clinical factors we collected in this study were included as routine clinical practice in the ED for patients with UGIB, missing data likely were minimal. Second, this study was conducted at a single tertiary referral center in Seoul, Korea. Therefore, the disease severity of the patients may have been skewed. Furthermore, a large proportion of patients had malignancy or cirrhosis. This made it difficult to evaluate only the effect of urgent endoscopy on outcomes. However, we included consecutive adult patients with acute nonvariceal UGIB during the study period, and the outcomes of the study subjects were comparable with those in other studies. Moreover, there was no difference in comorbidities between urgent and elective endoscopy groups.
In conclusion, urgent endoscopy within 6 hours or presentation was associated significantly with lower mortality but not with rebleeding in high-risk patients with acute nonvariceal UGIB. In addition to urgent endoscopy, failed primary endoscopic treatment, rebleeding, and comorbidities, including malignancy and cirrhosis, were independent predictors of mortality. In contrast, rebleeding was associated with high-risk endoscopic lesions and coagulopathy. Therefore, we suggest that urgent endoscopy may be beneficial for reducing mortality in select patients with nonvariceal UGIB.
